Prof. Mogher Khamaisi - Details

Mogher Khamaisi, MD, PhD, is Director of the Department of Internal Medicine “D” at Rambam Health Care Campus. He is also an Associate Professor at the Rappaport Faculty of Medicine of the Technion-Israel Institute of Technology, where he conducts basic and clinical research.

Prof. Khamaisi completed B.S., M.Sc., and Ph.D. degrees in biology from Ben-Gurion University in Beer Sheva, all with honors. He graduated from Ben-Gurion University Medical School and completed his residency in the Department of Internal Medicine “B” at Hadassah Hospital Ein-Kerem in Jerusalem. He also completed a fellowship in Endocrinology, Diabetes, and Metabolism at Rambam. A board certified specialist in both Internal Medicine and Endocrinology,Prof. Khamaisi completed a post-doctoral research fellowship at the Joslin Diabetes Center at Harvard Medical School, working with the Director of Research, George L. King, and head of the Vascular Cell Biology unit, and holds two patents from his work at Harvard.

Prof. Mourir Khamaisi

Prof. Khamaisi's research interests focus on diabetes and the molecular basis of related late-stage complications, particularly the mechanisms underlying diabetic wound healing. While at Harvard, he investigated human inducible stem cells from diabetic patients and their use in treatment of chronic complications, especially fibroblastic and angiogenic responses in wound healing. His laboratory studied the molecular mechanisms by which hyperglycemia and insulin resistance lead to vascular dysfunction and long-term complications, with the aims to further the identification and implementation of new treatment modalities. In his second project at Harvard, Prof. Khamaisi characterized fibroblast function and cytokine expression in response to ischemia and hyperglycemia in a mouse model, showing a significantly reduced epithelialization ratio into full-thickness wounds. He also examined insulin-induced expressions of vascular endothelial growth factor (VEGF) in fibroblasts from diabetics with or without vascular complications, as well as the effects of protein kinase C (PKC) on restoring insulin’s effect on protein kinase b (p-AKT) and VEGF secretion in diabetics. His results suggest that hyperglycemia can induce persistent activation of PKC-delta to inhibit insulin’s effect on fibroblasts and cause impaired wound healing in diabetes.

As a member of the Clinical Research Institute of Rambam (CRIR), Prof.. Khamaisi’s latest work in his lab continues to explore the molecular mechanisms involved in impaired wound healing in longstanding diabetes, particularly in chronic foot ulcer, a complication that leads to more than 2,000 amputations per year in Israel alone. He uses in vivo and in vitro studies, as well as human stem cells and other differentiated cells, to identify protective factors of diabetes-related vascular complications. His research currently utilizes inducible pluripotent stem cells (iPSCs) obtained from diabetics with longstanding disease, which differentiate into healthy endothelial cells and then are transplanted into a wound in an animal model.

In addition to his work on diabetic wound healing, Prof. Khaimaisi has completed works focusing on mechanisms of diabetic kidney function. His previous projects include the mechanisms of the regulation of intrarenal hemodynamics in diabetes and the pathophysiology and prevention of radio contrast nephropathy.

Prof. Khamaisi has received numerous research grants, most recently from the Israeli Academy of Sciences (ISF), as well as many scientific awards, including from Harvard Medical School for his research on the use of human-inducible stem cells for diabetic wound healing. Prof. Khamaisi has published over 75 scientific papers in prestigious international journals as well as book chapters and review articles, with the primary focus of diabetes and its complications. He has been a lecturer to medical students, nurses, and physicians in Israel for over 20 years and supervises graduate students (M.Sc. and PhD.), medical students (MD), and physicians in their research projects.


Selected Publications

  1. Khateeb J, Fuchs E, Khamaisi M. Diabetes and Lung Disease: A Neglected Relationship. Rev Diabet Stud. 2019;15:1-15. DOI: 10.1900/RDS.2019.15.1

  2. Gorelik Y, Yaseen H, Heyman SN, Khamaisi M. Negligible Risk of Acute Renal Failure Among Hospitalized Patients After Contrast-Enhanced Imaging With Iodinated Versus Gadolinium-Based Agents. Invest Radiol. 2019;54(5):312-8. DOI: 10.1097/RLI.0000000000000534

  3. Gorelik Y, Darawshi S, Yaseen H, Abassi Z, Heyman SN, Khamaisi M. Acute Renal Failure Following Near-Drowning. Kidney Int Rep. 2018;3(4):833-840. DOI: 10.1097/RLI.0000000000000534

  4. Kridin K, Khamaisi M, Comaneshter D, Batat E, Cohen AD. Autoimmune Thyroid Diseases and Thyroid Cancer in Pemphigus: A Big Data Analysis. Front Med (Lausanne). 2018;5:159. DOI: 10.3389/fmed.2018.00159

  5. Jenkins A, Lengyel I, Rutter GA, Lowe N, Shai I, Tirosh A, Petro T, Khamaisi M, Andrews S, Zmora N, Gross A, Maret W, Lewis EC, Moran A. Obesity, diabetes and zinc: A workshop promoting knowledge and collaboration between the UK and Israel, November 28-30, 2016 - Israel. J Trace Elem Med Biol. 2018;49:79-85. DOI: 10.1016/j.jtemb.2018.04.021(No abstract available.)

  6. Kridin K, Amber K, Khamaisi M, Comaneshter D, Batat E, Cohen AD. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Immunol Res. 2018;66(3):425-430. DOI: 10.1007/s12026-018-9005-8

  7. Granovsky Y, Nahman-Averbuch H, Khamaisi M, Granot M. Efficient conditioned pain modulation despite pain persistence in painful diabetic neuropathy. Pain Rep. 2017;2(3):e592. DOI: 10.1097/PR9.0000000000000592

  8. Heyman SN, Khamaisi M, Abassi Z. Interacting hypoxia and endothelin in the diabetic kidney: therapeutic options. Am J Physiol Renal Physiol. 2018 May 1;314(5):F699-F701. DOI: 10.1152/ajprenal.00598.2017 (No abstract available.)

  9. Heyman SN, Abassi Z, Rosenberger C, Yaseen H, Skarjinski G, Shina A, Mathia S, Krits N, Khamaisi M. Cyclosporine A induces endothelin-converting enzyme-1: Studies in vivo and in vitro. Acta Physiol (Oxf). 2018;223(1):e13033. DOI: 10.1111/apha.13033

  10. Shuker O, Khamaisi M. When patient/family expectations and hospital protocol conflict. Am J Med Sci. 2018;355(1):99-100. DOI: 10.1016/j.amjms.2017.01.012 (No abstract available.)

  11. Shan PF, Li Q, Khamaisi M, Qiang GF. Type 2 diabetes mellitus and macrovascular complications. Int J Endocrinol. 2017;2017:4301461. DOI: 10.1155/2017/4301461 (No abstract available.)

  12. Park K, Li Q, Evcimen ND, Rask-Madsen C, Maeda Y, Maddaloni E, Yokomizo H, Shinjo T, St-Louis R, Fu J, Gordin D, Khamaisi M, Pober D, Keenan H, King GL. Exogenous insulin infusion can decrease atherosclerosis in diabetic rodents by improving lipids, inflammation, and endothelial function. Arterioscler Thromb Vasc Biol. 2018;38(1):92-101. DOI: 10.1161/ATVBAHA.117.310291

  13. Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, Hughes TM, Craft S, Freedman BI, Bowden DW, Vinik AI, Casellini CM. Diabetic microvascular disease: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2017;102(12):4343-4410. DOI: 10.1210/jc.2017-01922 Review.

  14. Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman SN. Can SGLT2 Inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf. 2018 Mar;41(3):239-252. DOI: 10.1007/s40264-017-0602-6 Review.

  15. Maddaloni E, Xia Y, Park K, D'Eon S, Tinsley LJ, St-Louis R, Khamaisi M, Li Q, King GL, Keenan HA. High density lipoprotein modulates osteocalcin expression in circulating monocytes: a potential protective mechanism for cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol. 2017 Sep 16;16(1):116. DOI: 10.1186/s12933-017-0599-2

  16. Li Q, Park K, Xia Y, Matsumoto M, Qi W, Fu J, Yokomizo H, Khamaisi M, Wang X, Rask-Madsen C, King GL. Regulation of macrophage apoptosis and atherosclerosis by lipid-induced PKCδ isoform activation. Circ Res. 2017 Oct 27;121(10):1153-1167. DOI: 10.1161/CIRCRESAHA.117.311606

  17. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839-848. DOI: 10.1056/NEJMoa1616011

  18. Khamaisi M, Balanson S. Dysregulation of wound healing mechanisms in diabetes and the importance of negative pressure wound therapy (NPWT). Diabetes Metab Res Rev. 2017;33(7). DOI: 10.1002/dmrr.2929

  19. Kridin K, Grifat R, Khamaisi M. Is there an ethnic variation in the epidemiology of gonorrhoea? A retrospective population-based study from northern Israel over 15 years between 2001 and 2015. BMJ Open. 2017;7(6):e014265. DOI: 10.1136/bmjopen-2016-014265

  20. Gorelik Y, Paul M, Geffen Y, Khamaisi M. Urinary tract infections due to nontyphoidal salmonella. Am J Med Sci. 2017 Jun;353(6):529-532. DOI: 10.1016/j.amjms.2017.03.010

  21. Kridin K, Khamaisi M, Rishpon S, Grifat R. Striking ethnic variations in the epidemiology of Chlamydia trachomatis in Haifa District, Israel, throughout the years 2001-2015. Int J STD AIDS. 2017 Dec;28(14):1389-1396. DOI: 10.1177/0956462417706857

  22. Maddaloni E, D'Eon S, Hastings S, Tinsley LJ, Napoli N, Khamaisi M, Bouxsein ML, Fouda SMR, Keenan HA. Bone health in subjects with type 1 diabetes for more than 50 years. Acta Diabetol. 2017 May;54(5):479-488. DOI: 10.1007/s00592-017-0973-2

  23. doi: 10.1007/s00592-017-0973-2. Epub 2017 Feb 25.
  24. Khamaisi M, Balanson SE. Stem cells for diabetes complications: A future potential cure. Rambam Maimonides Med J. 2017;8(1). DOI: 10.5041/RMMJ.10283

  25. Heyman SN, Khamaisi M, Rosen S, Rosenberger C, Abassi Z. Potential hypoxic renal injury in patients with diabetes on SGLT2 Inhibitors: Caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care. 2017 Apr;40(4):e40-e41. DOI: 10.2337/dc16-2200 (No abstract available)

  26. Heyman SN, Khamaisi M, Rosenberger C, Szalat A, Abassi Z. Increased hematocrit during sodium-glucose cotransporter-2 inhibitor therapy. J Clin Med Res. 2017;9(2):176-177. DOI: 10.14740/jocmr2849w (No abstract available.)

  27. Qi W, Li Q, Liew CW, Rask-Madsen C, Lockhart SM, Rasmussen LM, Xia Y, Wang X, Khamaisi M, Croce K, King GL. SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes. Diabetologia. 2017 Mar;60(3):585-596. DOI: 10.1007/s00125-016-4159-1